A Retrospective Analysis of 53 Patients with Pathologic Stage II and III Endometrial Carcinoma

1982 ◽  
Vol 68 (4) ◽  
pp. 341-347 ◽  
Author(s):  
Giuseppe De Palo ◽  
Rado Kenda ◽  
Salvatore Andreola ◽  
Gaetano Bandieramonte ◽  
Luciano Luciani ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Retrospective Analysis ◽  
Myometrial Invasion ◽  
Stage Ii ◽  
Stage Iii ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Pathologic Stage ◽  
Factors Influencing ◽  
Degree Of Differentiation

From 1969 to 1977, 53 patients with surgical-pathologic stages II and III endometrial carcinoma were seen at the Istituto Nazionale Tumori of Milan. The treatment was individualized. The 5-year survival was 68.8% in stage II and 75.3% in stage III. The relapse-free survival was 68.9% and 69.4%, respectively. Adjuvant type of radiotherapy, degree of differentiation, depth of myometrial invasion, and especially sites of disease were the factors influencing survival.

Pilot Study with Adjuvant Hormone Therapy in Figo Stage I Endometrial Carcinoma with Myometrial Invasion

1983 ◽  
Vol 69 (1) ◽  
pp. 65-67 ◽  
Author(s):  
Giuseppe De Palo ◽  
Giovanni Battista Spatti ◽  
Gaetano Bandieramonte ◽  
Luciano Luciani
Keyword(s):  
Pilot Study ◽  
Hormone Therapy ◽  
Endometrial Carcinoma ◽  
Myometrial Invasion ◽  
Figo Stage ◽  
Stage I ◽  
Control Group ◽  
Relapse Free Survival ◽  
Adjuvant Hormone Therapy ◽  
Free Survival

A pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion was carried out. All patients received total abdominal hysterectomy and bilateral salpingo-oophorectomy plus complementary radium therapy on the vaginal stump. After the conventional treatment, patients were randomly allocated to adjuvant hormone therapy or no further treatment. Hormone therapy consisted of gestonorone caproate (17α-hydroxy-19-norpregn-4-en 3,20 dione caproate) administered i.m. at the dose of 200 mg/week for 1 year. Of the 62 patients who entered the study, 51 were considered evaluable (24 with adjuvant hormone therapy and 27 with no further treatment). Five patients had a relapse: four of these were in the group with no further treatment. Actuarial relapse-free survival analysis at 5 years was 95.7% in the group of adjuvant-treated patients and 82.8% in the control group. Although there is no statistical significance, adjuvant therapy appears to result in an increase in relapse-free survival in the group of patients with deep myometrial invasion and undifferentiated carcinoma. Further studies are necessary to assess the effectiveness of hormone adjuvant treatment in FIGO stage I endometrial carcinoma with myometrial invasion.

Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma

2008 ◽  
Vol 18 (5) ◽  
pp. 1071-1078 ◽  
Author(s):  
J. J. Jobsen ◽  
M.L.M. Lybeert ◽  
E. M. Van Der Steen-Banasik ◽  
A. Slot ◽  
J. Van Der Palen ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Endometrial Carcinoma ◽  
Disease Free Survival ◽  
Myometrial Invasion ◽  
Local Failure ◽  
Stage Ii ◽  
Significant Prognostic Factor ◽  
Multicenter Cohort Study ◽  
Free Survival ◽  
Grade 3

The aim of this study was to report outcome data and prognostic factors from a large cohort of pathologic stage II endometrioid type endometrial carcinoma. One hundred forty-two stage IIA–B patients were included. A central histopathologic review was performed. Follow-up ranged from 2 to 217 months with a median of 61 months. End points of the study were local and locoregional recurrence rates, distant metastasis–free survival (DMFS), disease-free survival (DFS), and disease-specific survival (DSS). The local failure rate was 5.1% for stage IIA patients and 10.8% for stage IIB patients. Grade was the only significant prognostic factor for local failure. With respect to DMFS, DFS, and DSS, grade 3 showed to be the most prominent prognostic factor in multivariate analyses. Lymphvascular space involvement combined with grades 3 and 2 and myometrial invasion greater than 0.5 also showed to be significant for DMFS and DFS. Our study showed grade 3 to be the most important single independent predictive factor for locoregional and distant recurrences in endometrial carcinoma stage II

Trattamento Radiante Elettivo del Carcinoma Mammario

1982 ◽  
Vol 68 (1) ◽  
pp. 73-80
Author(s):  
Carlo Nervi ◽  
Giorgio Arcangeli ◽  
Donatella Tirindelli Danesi ◽  
Giovanni Creton
Keyword(s):  
Breast Cancer ◽  
Distant Metastases ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Breast Cancers ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Negative Prognostic Factor ◽  
Intercurrent Disease

From March 1972 to November 1979 a total of 157 patients with stage I to III primary breast cancers have been irradiated after segmental resection (12 cases), tilectomy (89 cases) or biopsy (56 cases). Complete local control was achieved in all Stage I lesions, in 97 % Stage II lesions and in 68 % Stage III lesions. Non recurrence has been observed in patients previously operated by segmental resections, while local failures occurred in 6/89 and in 16/56 patients operated by tilectomy or biopsy, respectively. Of the 28 Stage I patients, 24 (86 %) are alive, one with distant metastases. Four patients of this group are dead, 2 of intercurrent disease and 2 of breast cancer. Of the 61 (Stage II) patients, 38 (62 %) are alive, 5 of these with distant metastases. Twenty-three patients are dead, 15 with active disease, and 8 suffered intercurrent death. Of the 68 Stage III patients, 21 (31 %) are alive, 6 of these with distant metastases. Fourty-seven patients are dead, 43 of breast cancer and 4 of intercurrent disease. The high probability of initial subclinical deposits is evidenced by the fact that 49 of the 68 patients in this group developed distant metastases. The patients with T1 lesions appear to comprise the most favourable group with a relapse free survival at five years of 76 %. The 5 years relapse free survival was 62 % for T2 lesions and 25 % for T3 and T4 lesions. N0 status does not confer the same favourable prognosis as T1 status. N+ status, however, resulted in a definitly negative prognostic factor. Cosmetic results after our treatment approach appear to be extremely good. A marked difference between the irradiated and controlateral breast occurred only in 10 of the 125 patients after a minium of 2 years observation.

LAPTM4B-35 Overexpression Is an Independent Prognostic Marker in Endometrial Carcinoma

2010 ◽  
Vol 20 (5) ◽  
pp. 745-750 ◽  
Author(s):  
Fan-ling Meng ◽  
Ming-zhu Yin ◽  
Hong-tao Song ◽  
Hua Yang ◽  
Ge Lou ◽  
...  
Keyword(s):  
Overall Survival ◽  
Endometrial Carcinoma ◽  
Cancer Progression ◽  
Histological Grade ◽  
Disease Free Survival ◽  
Myometrial Invasion ◽  
Normal Endometrium ◽  
Free Survival ◽  
Gynecology And Obstetrics ◽  
Disease Free

Background:Lysosomal protein transmembrane 4 β-35 (LAPTM4B-35), a novel oncoprotein that belongs to the mammalian 4-tetratransmembrane spanning protein superfamily, has been implicated in oncogenesis and cancer progression in several solid malignances. However, the expression of LAPTM4B-35 and its role in endometrial cancer progression remain unknown.Materials and Methods:We investigated the expression of the LAPTM4B-35 protein by immunohistochemistry in 30 normal endometrium specimens and 165 endometrial carcinomas and analyzed its correlation with various clinicopathologic features, including patient outcome.Results:LAPTM4B-35 immunoreactivity was overexpressed in endometrial carcinoma cases compared with normal endometrium (P < 0.001). High LAPTM4B-35 expression was found in 117 (70.91%) of these 165 carcinomas and was positively correlated with the International Federation of Gynecology and Obstetrics stage, histological grade, depth of myometrial invasion, lymph node metastasis, lymph vascular space involvement, and recurrence, but not with age and histological type. Patients with high LAPTM4B-35 expression had significantly poorer overall survival and disease-free survival compared with patients with low expression of LAPTM4B-35 (P = 0.001 and P = 0.002, respectively). Multivariate analysis showed that high LAPTM4B-35 expression was an independent prognostic factor for both overall survival and disease-free survival of patients with endometrial carcinoma (both P = 0.005).Conclusions:These results showed that high LAPTM4B-35 expression was associated with progression and prognosis of endometrial carcinoma.

DNA Image cytometry as a prognostic tool in stage II and stage III colorectal cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13565-13565
Author(s):  
A. Buhmeida ◽  
A. Ålgars ◽  
R. Ristamäki ◽  
Y. Collan ◽  
K. Syrjänen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Nuclear Dna Content ◽  
Image Cytometry ◽  
Stage Ii ◽  
Stage Iii ◽  
Computer Assisted ◽  
Primary Tumors ◽  
Free Survival ◽  
Wide Range ◽  
Dna Image Cytometry

13565 Background: We assessed the prognostic value of nuclear DNA content measured in the primary tumors of 123 patients with stage II or stage III colorectal cancer (CRC). Methods: Isolated nuclei from paraffin sections were stained with Feulgen and DNA was measured using a computer-assisted image analysis cytometry system (Ahrens ACAS). We applied 4 different approaches in analysis of DNA histograms: ABCDE approach, histogram range, peak evaluation, and DNA cut-off values. Results: Using the histogram range, narrow range was rare (3.7%) in patients who died of disease as compared with 16.4% among those alive (p=0.017). Modal peak evaluation was a significant predictor of disease free survival (DFS) (Kaplan-Meier log-rank p=0.0235). In the range evaluation, the first set (low-start gates) was a significant predictor of DFS (log-rank p=0.0121), where disease recurrence was closely associated the widest range (1.8c->10c) gates. Recurrence-free survival was markedly better among patients with narrow gate histograms than wide range histograms than among patients with wide range histograms (p<0.03). The first set also proved to be significant predictor of disease specific survival (DSS) (log-rank p=0.0045), being markedly better (78–90.0%) among the patients with the narrow-gate histograms. Grading of the histogram range into two categories (with 6.0c as cut-off for low and wide range), was a powerful predictor of both DSS (log-rank p= 0.0092) and 5-year DFS (p=0.0106) in the whole series, and separately in Stage III (but not Stage II) disease; p=0.0131 and p=0.0201, respectively. Conclusions: The DNA image cytometry with careful analysis of the histograms may provide valuable prognostic information in CRC, with potential clinical implications in patient management, particularly in predicting the patients at high risk for recurrence who should be considered as candidates for adjuvant therapy. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document